OpenAI launches GPT-Rosalind, a specialised AI model for drug discovery and life sciences research

Named after the crystallographer who helped reveal the structure of DNA, GPT-Rosalind is OpenAI’s first domain-specific model series, fine-tuned for biochemistry, genomics, and protein engineering. Access is restricted to a trusted-access programme for vetted enterprise customers including Amgen, Moderna, and Thermo Fisher Scientific.

OpenAI has launched GPT-Rosalind, a frontier reasoning model built specifically for life sciences research, the company announced on Thursday. 

The model is designed to support evidence synthesis, hypothesis generation, experimental planning, and multi-step scientific workflows across biochemistry, genomics, and protein engineering, representing OpenAI’s first purpose-built domain-specific model series.

It is available as a research preview in ChatGPT, Codex, and the OpenAI API, but access is restricted to a trusted-access programme for qualified enterprise customers in the United States.

The model is named after Rosalind Franklin, the British chemist and X-ray crystallographer whose diffraction imaging of DNA was instrumental in revealing the double helix structure, and ...